Joincare Pharmaceutical Group Industry Co.,Ltd.

$ 9.81 0.31 %

Joincare Pharmaceutical Group Industry Co., Ltd. is a Chinese enterprise primarily focused on the comprehensive process of researching, developing, producing, and commercializing pharmaceutical and healthcare products within China. The company boasts a broad pharmaceutical portfolio that includes both Western chemical drug preparations, addressing conditions such as respiratory, gastrointestinal, anti-infection, gonadotropic, and psychiatric disorders, as well as traditional Chinese medicines (TCM), with offerings for anti-tumor and cold relief. Beyond finished drugs, Joincare supplies chemical active pharmaceutical ingredients (APIs) and intermediates. Its operations also extend into the diagnostics sector, where it provides specialized reagents and equipment, such as an autoimmunity multiple detection platform and an IgM diagnostic kit. Furthermore, the company markets a range of health and wellness products, exemplified by American ginseng tea and Jingxin menocare essence. Joincare diversifies its business by engaging in the wholesale and retail of personal care items, including skincare products, cosmetics, and various other essential goods. Its products are available in diverse formats, such as hormone tablets, oral liquid formulations, and standard tablets. Established in 1992, Joincare Pharmaceutical Group maintains its principal offices in Shenzhen, China.

CEO: Nanqi Lin - https://www.joincare.com

Price objectif

-

Recommandation

-

DCF

$ 31.94

Loading data...

600380.SS vs S&P500

Loading data...

No data available.

Quick ratio

2.14

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

13.44

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.73

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

8.72 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

9.00 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

4.57

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.33

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

1.79

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

18.58 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
2.59 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.38 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.14 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.